B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.617.2, emerged in India and has spread to over 80 countries. B.1.617.2 replaced B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep increase in new infections, and a similar development is expected for other countries. Effective countermeasures require information on susceptibility of B.1.617.2 to control by antibodies elicited by vaccines and used for coronavirus disease 2019 (COVID-19) therapy. We show, using pseudotyping, that B.1.617.2 evades control by antibodies induced upon infection and BNT162b2 vaccination, although to a lesser extent as compared to B.1.351. We find that B.1.617.2 is resistant against bamlanivimab, a monoclonal antibody with emergency use authorization for COVID-19 therapy. Finally, we show increased Calu-3 lung cell entry and enhanced cell-to-cell fusion of B.1.617.2, which may contribute to augmented transmissibility and pathogenicity of this variant. These results identify B.1.617.2 as an immune evasion variant with increased capacity to enter and fuse lung cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · cited 1×
“Furthermore, antibodies directed against epitopes outside the RBD, mainly within the N-terminal domain of the S1 subunit, may sterically block S protein binding to ACE2, lock the S protein in a conformational state that does not allow the RBD to interact with ACE2, or abrogate S protein transition from the pre-fusion…”
BackgroundA human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
Self-citationBarnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · cited 1×
“For one, antibodies targeting the receptor binding domain (RBD) can directly block S protein binding to its cellular receptor angiotensin-converting enzyme 2 (ACE2) (Barnes et al., 2020).”
BackgroundSelf-citation
Research works printed but not linked: 13
- Bussani, 2020, Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology, EBioMedicine, 61, 103104, 10.1016/j.ebiom.2020.103104 · DOI · Paper page
- Campbell, 2021, Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021, Euro Surveill., 26, 2100509, 10.2807/1560-7917.ES.2021.26.24.2100509 · DOI · Paper page
- Golob, 2021, SARS-CoV-2 vaccines: a triumph of science and collaboration, JCI Insight, 6, e149187, 10.1172/jci.insight.149187 · DOI
- Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Jones, 2020, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv
- Liu, 2021, BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants, Nature, 596, 273, 10.1038/s41586-021-03693-y · DOI · Paper page
- Plante, 2021, The variant gambit: COVID-19's next move, Cell Host Microbe, 29, 508, 10.1016/j.chom.2021.02.020 · DOI · Paper page
- Singh, 2021, SARS-CoV-2 variants of concern are emerging in India, Nat. Med., 27, 1131, 10.1038/s41591-021-01397-4 · DOI · Paper page
- Suryadevara, 2021, Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein, Cell, 184, 2316, 10.1016/j.cell.2021.03.029 · DOI · Paper page
- Tian, 2020, Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer, J. Thorac. Oncol., 15, 700, 10.1016/j.jtho.2020.02.010 · DOI · Paper page
- Wang, 2021, Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries, Genomics, 113, 2158, 10.1016/j.ygeno.2021.05.006 · DOI · Paper page
- Xia, 2021, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, Lancet Infect. Dis., 21, 39, 10.1016/S1473-3099(20)30831-8 · DOI · Paper page
- Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med., 8, 420, 10.1016/S2213-2600(20)30076-X · DOI · Paper page
Cited by
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
Self-citationZhao, H., Lu, L., Peng, Z., Chen, L.-L., Meng, X., Zhang, C., Ip, J. D., Chan, W.-M., Chu, A. W.-H., Chan, K.-H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2023329 · Cited by 413
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 269
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., & Pöhlmann, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01891-2 · Cited by 27
Self-citation
Metadata
- Authors
- Arora, P., Sidarovich, A., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S., Jäck, H.-M., Stankov, M. V., Behrens, G. M. N., Pöhlmann, S., & Hoffmann, M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 37
- Issue
- 2
- Pages
- 109825
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3202256154
- Cited by
- 76
- References
- 19
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Deutsche Forschungsgemeinschaft (01KI2074A, PO 716/11-1, PO 716/14-1, RTG1660, TRR130)
- Bundesministerium für Bildung und Forschung (01KI2006D, 01KI20328A, 01KI20396, 01KX2021)
- Bundesministerium fur Bildung und Forschung Dienststelle Berlin (01KI2043)
- Niedersächsisches Ministerium für Wissenschaft und Kultur (14-76103-184, MWK HZI COVID-19)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.